Volume 30, Number 6—June 2024
Dispatch
Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence, Japan, 2023
Figure 2

Figure 2. Age-stratified weighted concentrations of spike SARS-Cov-2 antibody stratified by nucleocapsid SARS-Cov-2 antibody seroprevalence in Japan, 2023. A) Spike antibody concentrations stratified by nucleocapsid antibody seroprevalence in persons 6 months to >95 years of age. Red dashed box represents the age group analyzed in panel B. B) Spike antibody concentrations stratified by nucleocapsid antibody seroprevalence in persons 6 months to 4 years of age. Horizonal lines within boxes indicate the median, box tops and bottoms indicate the 75th percentile and 25th percentile, and whiskers extend to 1.5 times the interquartile range (IQR) from 25th percentile and 75th percentile. Dotted horizontal lines represent the cutoff index of 0.8 U/mL. Box plots are weighted with respect to the demographics of Japan.
1These first authors contributed equally to this article.
2These senior authors contributed equally to this article.